↓ Skip to main content

TREK-King the Blood–Brain-Barrier

Overview of attention for article published in Journal of Neuroimmune Pharmacology, February 2014
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
81 Mendeley
Title
TREK-King the Blood–Brain-Barrier
Published in
Journal of Neuroimmune Pharmacology, February 2014
DOI 10.1007/s11481-014-9530-8
Pubmed ID
Authors

Stefan Bittner, Tobias Ruck, Juncal Fernández-Orth, Sven G. Meuth

Abstract

TWIK-related potassium channel-1 (TREK1, KCNK2) is the most extensively studied member of the two-pore domain potassium (K2P) channel family. Recent studies have already demonstrated a key role in the pathophysiology of depression, pain and neurodegenerative damage pointing towards an important role in a broad spectrum of CNS disorders. The mammalian blood-brain barrier (BBB) is a highly specialized structure and an integral part of the neurovascular unit, which controls the transition of cells and molecules into the CNS. While BBB dysregulation is common in neurologic diseases, the molecular mechanisms involved in this process remain largely unknown. Recently, we were able to describe a role of TREK1 in this context. TREK1 was downregulated in murine and human BBB upon inflammation. Blocking of TREK1 increased lymphocyte migration, while activation had the opposite effect. In TREK1-deficient (Trek1 (-/-) ) mice, brain endothelial cells displayed an inflammatory phenotype and leukocyte trafficking was facilitated, as demonstrated in experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis. Here we summarize these findings and discuss the implications in diseases related to BBB dysfunction.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Korea, Republic of 1 1%
Mexico 1 1%
Unknown 79 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 21%
Student > Ph. D. Student 13 16%
Student > Master 11 14%
Student > Doctoral Student 8 10%
Student > Bachelor 6 7%
Other 12 15%
Unknown 14 17%
Readers by discipline Count As %
Agricultural and Biological Sciences 19 23%
Medicine and Dentistry 11 14%
Neuroscience 10 12%
Biochemistry, Genetics and Molecular Biology 9 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 6%
Other 10 12%
Unknown 17 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 February 2014.
All research outputs
#19,702,729
of 24,217,893 outputs
Outputs from Journal of Neuroimmune Pharmacology
#453
of 583 outputs
Outputs of similar age
#169,178
of 229,235 outputs
Outputs of similar age from Journal of Neuroimmune Pharmacology
#6
of 8 outputs
Altmetric has tracked 24,217,893 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 583 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 229,235 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.